On August 25-27, 2026, CPHI Korea 2026 (World Pharmaceutical Ingredients Korea Exhibition) was grandly opened at the COEX Convention and Exhibition Center in Seoul, South Korea. As one of the largest and most influential pharmaceutical raw material exhibitions in Asia, the exhibition area reached 13,000 square meters, gathering more than 370 exhibitors from more than 80 countries and regions around the world, and 10,200 professional visitors. The diversified exhibition structure not only brings a wealth of exhibits and cutting-edge technologies, but also builds a broad communication and cooperation platform for exhibitors and visitors. At this industry event, Suzhou Biosynergy Pharmaceutical Co., Ltd. also made a wonderful appearance, attending this annual appointment in the field of pharmaceutical raw materials with global partners.
Suzhou Biosynergy Pharmaceutical has participated in pharmaceutical exhibitions for many years. As a full-link partner from molecular discovery, process development to commercial production, it focuses on the R&D and production of biomedicine, high-end pharmaceutical intermediates and APIs, covering monoclonal antibodies, ADCs, small molecule toxins, and mRNA Vaccine nucleoside raw materials and high-end generic drugs, the main products cover the four major fields of peptides/GLP-1, antibodies, ADCs and biosimilars. We are committed to working with global customers with high-quality products and professional services to jointly promote the development of the biopharmaceutical industry.
At this exhibition, Suzhou Biosynergy Pharmaceutical has been officially approved by KDMF as a first-line influenza drug. Oseltamivir has become the focus of attention in this exhibition. Many exhibiting customers have had in-depth exchanges around its technical indicators and application prospects. In addition to oseltamivir, our core products ADC small molecule toxins and peptides have also attracted much attention, especially It is a GLP-1 and related receptor agonist represented by semaglutide, tilpotide, and retalglutide. Negotiations on the demand for generic drugs and APIs, as well as the drug market, etc. are intense. With this international platform, Biosynergy Pharmaceutical Biotech has further established contacts with customers in multiple markets such as South Korea, Europe, the United States, and Southeast Asia to expand global cooperation space.
The three-day exhibition came to a successful conclusion. Through this exhibition, Suzhou Biosynergy Pharmaceutical not only deepened customers' understanding and recognition of the company's products, but also established more stable cooperative relationships with partners from different countries, laying a solid foundation for subsequent in-depth cooperation. We will continue to uphold the business philosophy of "integrity, professionalism, innovation", work together with our partners to develop together, and continue to write a new chapter of mutual benefit and win-win!